Voyager Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates
09 nov. 2020 16h00 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR) today reported its third quarter 2020 financial results, program progress and corporate updates. ...
Voyager Therapeutics Provides Regulatory Update on VY-HTT01 Program
12 oct. 2020 16h01 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 oct. 2020 16h01 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics Appoints Nancy Vitale to its Board of Directors
15 sept. 2020 16h01 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics Appoints Michelle Quinn Smith as Chief Human Resources Officer
14 sept. 2020 16h30 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson’s Disease
11 sept. 2020 11h36 HE
|
Voyager Therapeutics, Inc.
-- Data for Investigational Gene Therapy Treatment NBIb-1817 (VY-AADC) Presented at the MDS Virtual Congress 2020 -- NBIb-1817 Treatment Showed Sustained Improvement in Motor Function, Including...
Voyager Therapeutics Announces Upcoming Presentations at the International Parkinson and Movement Disorder Society Virtual Congress 2020
03 sept. 2020 16h29 HE
|
Voyager Therapeutics, Inc.
New Phase 1b Data of Investigational Gene Therapy Compound, VY-AADC (NBIb-1817), Evaluating Three-Year Safety and Clinical Outcomes in Patients with Advanced Parkinson’s Disease Voyager to...
Voyager Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates
10 août 2020 07h00 HE
|
Voyager Therapeutics, Inc.
Plans to present three-year Phase 1b results of VY-AADC (NBIb-1817) in patients with Parkinson’s disease at the Movement Disorder Society (MDS) Virtual Congress 2020 ...
Voyager Therapeutics to Report Second Quarter 2020 Financial Results and Participate in Upcoming Investor Conferences
03 août 2020 16h30 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics Provides Update on AbbVie Vectorized Antibody Collaborations
03 août 2020 16h01 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...